Please select the option that best describes you:

When and how are you incorporating tumor sequencing to plan treatment of metastatic prostate cancer?  

Given the FDA approvals for PARP inhibitors and combinations in mCRPC, when do you obtain NGS for mCRPC? Do you have a preferred assay?



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Duke University School of Medicine
I agree with this. Truly actionable mutations in ...
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at Geisinger Medical Center
In a patient with prostate cancer with only bone m...
Sign in or Register to read more

Answer from: at Community Practice
Sign in or Register to read more